COVID-19: a potential driver of immune-mediated breast cancer recurrence?

Breast Cancer Res. 2020 Oct 30;22(1):117. doi: 10.1186/s13058-020-01360-0.

Abstract

Severe coronavirus disease 2019 (COVID-19) causes a hyperactivation of immune cells, resulting in lung inflammation. Recent studies showed that COVID-19 induces the production of factors previously implicated in the reawakening of dormant breast cancer cells such as neutrophil extracellular traps (NETs). The presence of NETs and of a pro-inflammatory microenvironment may therefore promote breast cancer reactivation, increasing the risk of pulmonary metastasis. Further studies will be required to confirm the link between COVID-19 and cancer recurrence. However, an increased awareness on the potential risks for breast cancer patients with COVID-19 may lead to improved treatment strategies to prevent metastatic relapse.

Keywords: Breast cancer; COVID-19; Disseminated tumor cells; Dormancy; Inflammation; Metastasis; Metastatic reawakening; Relapse; Tumor recurrence.

MeSH terms

  • Betacoronavirus / immunology
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / virology*
  • COVID-19
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / virology
  • Extracellular Traps / immunology
  • Female
  • Humans
  • Lung / immunology
  • Lung / pathology
  • Neoplasm Recurrence, Local / immunology*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / virology*
  • Neutrophils / immunology
  • Pandemics
  • Pneumonia / immunology
  • Pneumonia / virology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Tumor Microenvironment / immunology